Uterine Artery Embolisation for Symptomatic Adenomyosis with Polyzene F-Coated Hydrogel Microspheres: Three-Year Clinical Follow-Up Using UFS–QoL Questionnaire
- 684 Downloads
This study was designed to assess midterm outcome of uterine artery embolisation (UAE) for women with therapy-resistant adenomyosis using polyzene F-coated hydrogel microspheres.
Between September 2006 and January 2010, 29 consecutive women with adenomyosis (15 in combination with fibroids) were treated with UAE using polyzene F-coated hydrogel microspheres. Junction zone thickness was assessed with MRI at baseline and 3 months. Women filled out the uterine fibroid symptom and quality of life questionnaire at baseline, 3 months and after a mean clinical follow-up of 37 months (median 35, range 29–64 months).
At baseline, symptom severity score of 29 women was mean 67 (median 72, range 23–100). At 3 months, this score decreased to mean 22 (median 15, range 0–66) and mean 15 (median 17, range 0–34) at final follow-up. At final follow-up of mean 37 months (median 35, range 29–64 months), 22 of 29 (76 %) patients were asymptomatic. Of these 22 women, 3 underwent a second UAE at 6, 7, and 14 months. The remaining seven patients clinically improved but still had symptoms; one underwent a hysterectomy. There was no difference in outcome between women with pure adenomyosis and women with additional fibroids. The junction zone of 4 women with additional therapy was significantly thicker compared with the remaining 25 patients.
In women with therapy resistant adenomyosis, UAE using polyzene F-coated hydrogel microspheres resulted in 3 years preservation of the uterus in 28 of 29 (97 %) with good clinical outcome in the vast majority of patients. Initial thickness of the junction zone is related to additional therapy.
KeywordsClinical practice Arterial intervention Embolisation Urogenital
Conflict of interest
Nijenhuis, Smeets, Morpurgo, Boekkooi, Reuwer, Smink, and van Rooij has no conflict of interest. Lohle Consultant for Celonova Bio Sciences, San Antonio, TX.
- 1.Azzir R (1989) Adenomyosis: current perspectives. Obstet Gynecol Clin N Am 16:221–235Google Scholar
- 7.Lohle PN, De Vries J, Klazen CA et al (2007) Uterine artery embolization for symptomatic adenomyosis with or without uterine leiomyomas with the use of calibrated tris-acryl gelatin microspheres: midterm clinical and MR imaging follow-up. J Vasc Interv Radiol 18(7):835–841PubMedCrossRefGoogle Scholar
- 15.Spies J, Niedzwiecki G, Goodwin S et al (2001) Training standards for physicians performing uterine artery embolisation for leiomyomata: consensus statement developed by the Task Force on Uterine Artery Embolisation and the standards division of the Society of Cardiovascular and Interventional Radiology. J Vasc Interv Radiol 12(1):19–21PubMedCrossRefGoogle Scholar
- 16.Worthington-Kirsch R, Spies JB, Myers ER et al (2005) The Fibroid Registry for outcomes data (FIBROID) for uterine embolisation: short-term outcomes. Obstet Gynecol 106(1):52–59. Erratum in: Obstet Gynecol 106(4):869Google Scholar
- 26.Dutton S, Hirst A, McPherson K, Nicholson T, Maresh MA (2007) A UK multicentre retrospective cohort study comparing hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids (HOPEFUL study): main results on medium-term safety and efficacy. BJOG 114:1340–1351PubMedCrossRefGoogle Scholar